Committee on the Review of Medicines. Recommendations on phenylbutazone, oxyphenbutazone, feprazone, allopurinol, colchicine, probenecid, and sulphinpyrazone.
D000328:Adult; D000493:Allopurinol / Q000009:adverse effects / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002648:Child; D003078:Colchicine / Q000009:adverse effects / Q000627:therapeutic use; D004341:Drug Evaluation; D011298:Feprazone / Q000009:adverse effects / Q000627:therapeutic use; D006074:Gout Suppressants / Q000627:therapeutic use*; D006801:Humans; D010113:Oxyphenbutazone / Q000009:adverse effects / Q000627:therapeutic use; D010653:Phenylbutazone / Q000009:adverse effects / Q000627:therapeutic use; D011339:Probenecid / Q000009:adverse effects / Q000627:therapeutic use; D013442:Sulfinpyrazone / Q000009:adverse effects / Q000627:therapeutic use; D006113:United Kingdom
D000894:Anti-Inflammatory Agents, Non-Steroidal; D006074:Gout Suppressants; D000493:Allopurinol; D011298:Feprazone; D010653:Phenylbutazone; D010113:Oxyphenbutazone; D011339:Probenecid; D003078:Colchicine; D013442:Sulfinpyrazone